Clinico-biochemical correlation between psoriasis and lipid profile


  • Amita Gupta Department of Clinical Biochemistry, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh
  • Sangita Paneri Department of Clinical Biochemistry, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh
  • Rajeev Lohokare Department of Clinical Biochemistry, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh
  • P. Dey Sarkar Department of Clinical Biochemistry, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh
  • Anil Jain Department of Clinical Biochemistry, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh



Psoriasis, PASI, Lipid profile, Dyslipidemia


Background: Psoriasis is an autoimmune disorder associated with alteration of different metabolism. The present study was aimed to assess the lipid metabolism and its correlation with severity of disease and associated cardiovascular risk factors in psoriasis.

Methods: Study comprises total of 60 cases of psoriasis attended the dermatology clinics at Maharaja Yashwant Rao hospital, Indore, Madhya Pradesh, India and 30 age, gender matched healthy controls. Subjects were enrolled in the study as per the inclusion criteria. Severity of the disease was assessed by PASI score. Fasting blood samples were collected and evaluated for Lipid profile and risk ratio was calculated.

Results: The results indicated that serum total cholesterol, triglycerides, LDL-C,VLDL-C were significantly increased in moderate to severe cases in comparison to control and level of HDL-C significantly decreased in moderate psoriasis and highly significant decreased was observed in severe cases when compared to control. Serum triglyceride (TG), total cholesterol, low density lipoprotein showed a significant positive correlation with severity of psoriasis. Study concludes that lipid derangement correlate with the severity of disease and also acts as a good prognostic sign.  

Conclusions: Present study concludes that psoriatic patients should be evaluated and followed up for the risk of dyslipidemia and cardiovascular morbidity.


Christopher E, Kruger G. Psoriasis. In: Fitzpatrick TB, Eisen AZ, Wollf K, Eds. Dermatology In General Medicine. 3rd Ed. New York: Mc Graw-Hill 1987;465.

Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52:23-6.

Pietrzak A, Lecewicz-Tourn B. Activity of serum Lipase and the diversity of serum lipid profile in Psoriasis. Med Sci Monit. 2002;8:CR9-13.

Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005;64(2):ii30-6.

University of California, Davis, Department of Dermatology. Psoriasis retrieved 2013. dermatology/ medical/ psoriasis.html.

Seckin D, Tokgozoglu L, Akkaya S. Are lipoprotein profile and lipoprotein(a) level altered in men with psoriasis? J Am Acad Dermatol. 1994;31:445-9.

Seishima M, Moris S, Noma A. Serum lipid and apolipoprotein levels in patients of psoriasis. Br J Dermatol. 1994;130:738-42.

Gurkok F, Piskin S, Ekuklu G. Serum lipid and lipoprotein levels in psoriasis. Bull Leprosy 1999;30:105-11.

Proksch E. Antilipemic drug induced skin manifestations. Hautarzt. 1995;2:76-80.

Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol. 2007;87:506-9.

Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: A population- based study. Acta Derm Venereol. 2008; 88 :561-5.

Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829-35.

Farshchian M, Zamanian A, Farshchian M, Monsef AR, Mahjub H. Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol. 2007;21:802-5.

Bajaj DR, Mahesar SM, Devrajani BR, Iqbal MP. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. J Pak Assoc Dermatol. 2009;59:512-5.

Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007;21:1330-2

Javidi Z, Meibodi NT, Nahidi Y. Serum lipids abnormalities and psoriasis. Indian J Dermatol. 2007;52:89-92.

Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J. 2003;44:24-6.

Mallbris L, Granath F, Hamsten A, Stahl M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54:614-21.

Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm. 2007;2007 :78454.

Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-07.

Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352:1899-1912.

Federman DG, Shelling M, Prodanovich S, Gunderson CG, Kirsner RS. Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol. 2009;160(1):1-7.

Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006;24(1 Suppl 40):S72-8.

Terui T, Ozawa M, Tagami H. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation boosting loop. Exp Dermatol. 2000;9:1-10.

Orem A, Cimsit G, Deger O, Vanizor B. The significance of autoantibodies against oxidatively modified LDL in patients with psoriasis. Clin Chim Acta. 1999;284:81-8.

Takeda H, Okuho M, Hoga M, Aizawa K. Lipid analysis of peripheral blood monocytes in psoriatic patients using fourier transform infrared microspectroscopy. J Dermatol. 2001;28:303-11.

Dreiher J, Weitzman D, Shapiro J, Davidovici B, and Cohen AD. “Psoriasis and chronic obstructive pulmonary disease: a case-control study,” British Journal of Dermatology. 2008;159(4):956-60.

Wysocki J, Nski SS, ozik AS, Hochuł B, Zyguła M. “Metabolic or immunometabolic syndrome?” Wiadomosci Lekarskie. 2005;58(1-2):124-7.

Gisondi P, Fantin F, Del Giglio M, Valbusa F, Marino F, Zamboni M, et al. “Chronic plaque psoriasis is associated with increased arterial stiffness,” Dermatology. 2009;218(2):110-3.

Zalewska A, Głowacka E, Ołkowska JW, Orzewski HT, Narbutt J, Edrzejowska AS. “Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis,” Mediators of Inflammation. 2006(2006). Article ID 81767, 6 pages.

Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994;102:145-9.

Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U et al. Cytokines expression in advanced human atherosclerotic plaques: Dominance of pro- inflammatory (Th1) and macrophage stimulating cytokines. Atherosclerosis. 1999;145:33-43.




How to Cite

Gupta, A., Paneri, S., Lohokare, R., Sarkar, P. D., & Jain, A. (2017). Clinico-biochemical correlation between psoriasis and lipid profile. International Journal of Research in Medical Sciences, 4(6), 1966–1969.



Original Research Articles